LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval MT
US FDA approves Bristol Myers' colorectal cancer therapy RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo MT
Bristol Myers: application validated for subcutaneous Opdivo CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024 CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment MT
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5 MT
Bristol Myers: Board declares dividend CF
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024 CI
Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors CI
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial MT
Geron shares surge after U.S. FDA approves blood disorder drug RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
Chart Bristol-Myers Squibb Company
More charts
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.93 USD
Average target price
53.19 USD
Spread / Average Target
+26.87%
Consensus
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab